跳至主要内容
临床试验/ACTRN12612000663853
ACTRN12612000663853招募中4 期

Does Metformin potentiate the effect of Rosuvastatin therapy on biochemical markers in Patients with Polycystic Ovary Syndrome? A prospective randomized, double-blinded, placebo-controlled study

American University of Beirut0 个研究点目标入组 54 人开始时间: 2012年6月21日最近更新:
适应症

试验速览

阶段
4 期
状态
招募中
入组人数
54

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 55 Years(—)
性别
Female

入选标准

  • adult females aged 18-55, diagnosed as having PCOS, not planning to conceive

排除标准

  • patients with cushing's syndrome, hyperprolactinemia, diabetes mellitus, thyroid disease, adrenal hyperplesia, androgen secretingtumors or other endocrinopathies, cancer, kidney or liver disease, and smokers. Patients who have also been treated with hormone medications or any other medication that could interfere with ovarian function, insulin sensitivity and lipid profile within the 3 months prior to their entry into the study are also be excluded. Moreover, since the effect of metformin may be less in subjects with a mean BMI of > 34 kg/m2 and thus pose as a limitation to the study results, patients with a BMI of >34 kg/m2 will be excluded from participation in the study.

研究者

相似试验